R M Freidinger - JoVE Visualize

Showing results (31-40 of 40) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 40 results.

Biochemical and Biophysical Research Communications|October 14, 1988

HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteinsP L Darke, R F Nutt, S F Brady, et al.

Journal of Medicinal Chemistry|October 1, 1986

Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubilityM G Bock, R M DiPardo, K E Rittle, et al.

Bioorganic & Medicinal Chemistry Letters|January 5, 1999

Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminusM S Kuo, M G Bock, R M Freidinger, et al.

Bioorganic & Medicinal Chemistry Letters|August 11, 2000

Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-onesP G Nantermet, J C Barrow, H G Selnick, et al.

Bioorganic & Medicinal Chemistry Letters|October 10, 2001

Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonistsJ C Barrow, P G Nantermet, H G Selnick, et al.

Journal of Medicinal Chemistry|June 17, 1998

Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridinesI M Bell, J M Erb, R M Freidinger, et al.

Bioorganic & Medicinal Chemistry Letters|May 26, 1999

Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potencyP D Williams, M G Bock, B E Evans, et al.

Journal of Medicinal Chemistry|November 26, 1997

Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 positionD M Feng, S J Gardell, S D Lewis, et al.

Journal of Medicinal Chemistry|July 14, 2000

In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasiaJ C Barrow, P G Nantermet, H G Selnick, et al.

Proceedings of the National Academy of Sciences of the United States of America|September 2, 1998

Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2L Yang, S C Berk, S P Rohrer, et al.

Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 40 results.

Biochemical and Biophysical Research Communications|October 14, 1988

HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteinsP L Darke, R F Nutt, S F Brady, et al.

Journal of Medicinal Chemistry|October 1, 1986

Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubilityM G Bock, R M DiPardo, K E Rittle, et al.

Bioorganic & Medicinal Chemistry Letters|January 5, 1999

Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminusM S Kuo, M G Bock, R M Freidinger, et al.

Bioorganic & Medicinal Chemistry Letters|August 11, 2000

Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-onesP G Nantermet, J C Barrow, H G Selnick, et al.

Bioorganic & Medicinal Chemistry Letters|October 10, 2001

Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonistsJ C Barrow, P G Nantermet, H G Selnick, et al.

Journal of Medicinal Chemistry|June 17, 1998

Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridinesI M Bell, J M Erb, R M Freidinger, et al.

Bioorganic & Medicinal Chemistry Letters|May 26, 1999

Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potencyP D Williams, M G Bock, B E Evans, et al.

Journal of Medicinal Chemistry|November 26, 1997

Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 positionD M Feng, S J Gardell, S D Lewis, et al.

Journal of Medicinal Chemistry|July 14, 2000

In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasiaJ C Barrow, P G Nantermet, H G Selnick, et al.

Proceedings of the National Academy of Sciences of the United States of America|September 2, 1998

Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2L Yang, S C Berk, S P Rohrer, et al.

Pageof 4